These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15493002)

  • 1. Clinical use of positron emission tomography in the management of cutaneous melanoma.
    Friedman KP; Wahl RL
    Semin Nucl Med; 2004 Oct; 34(4):242-53. PubMed ID: 15493002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma.
    Kumar R; Alavi A
    Curr Opin Oncol; 2005 Mar; 17(2):154-9. PubMed ID: 15725921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node.
    Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F
    Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
    J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of FDG PET-CT in cutaneous melanoma].
    Nicol I; Chuto G; Gaudy-Marqueste C; Brenot-Rossi I; Grob JJ; Richard MA
    Bull Cancer; 2008 Nov; 95(11):1089-101. PubMed ID: 19036682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
    Abbott RA; Acland KM; Harries M; O'Doherty M
    Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorodeoxyglucose-PET in the management of malignant melanoma.
    Kumar R; Mavi A; Bural G; Alavi A
    Radiol Clin North Am; 2005 Jan; 43(1):23-33. PubMed ID: 15693645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
    Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis.
    Rodriguez Rivera AM; Alabbas H; Ramjaun A; Meguerditchian AN
    Surg Oncol; 2014 Mar; 23(1):11-6. PubMed ID: 24556310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma.
    Uren RF; Howman-Giles R; Chung D; Thompson JF
    J Surg Oncol; 2011 Sep; 104(4):405-19. PubMed ID: 21858836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of FDG-PET in the assessment of survival prognosis in melanoma.
    Pleiss C; Risse JH; Biersack HJ; Bender H
    Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma: A National Cohort Study of 1480 Patients.
    Helvind NM; Weitemeyer MB; Chakera AH; Hendel HW; Ellebæk E; Svane IM; Kjærskov MW; Bojesen S; Skyum H; Petersen SK; Bastholt L; Johansen C; Bidstrup PE; Hölmich LR
    Ann Surg Oncol; 2023 Apr; 30(4):2377-2388. PubMed ID: 36752970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.
    Siggelkow W; Rath W; Buell U; Zimny M
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S118-24. PubMed ID: 15146295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
    Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
    J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma.
    Bikhchandani J; Wood J; Richards AT; Smith RB
    Head Neck; 2014 Sep; 36(9):1313-6. PubMed ID: 23956077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Melanoma and Skin Malignancies.
    Lee ST; Kovaleva N; Senko C; Kee D; Scott AM
    PET Clin; 2024 Apr; 19(2):231-248. PubMed ID: 38233284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma.
    Clark PB; Soo V; Kraas J; Shen P; Levine EA
    Arch Surg; 2006 Mar; 141(3):284-8. PubMed ID: 16549694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.